Clinical Trials · NCT03600480
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 96
- Start date
- Jul 2018
- Locations
- 1 site, United States
- Primary endpoint
- Number of treatment emergent adverse events (TEAEs)